Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Infectious diseases · J Infect Dis · 2026-09-23
Secondary analysisn = 1,227
Diamond et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNAInfectious diseases · Clin Infect Dis · 2026-09-02
RCTn = 494
Landovitz et al. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 StudyInfectious diseases · Lancet · 2026-08-12
RCTn = 634
Colson et al. Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trialInfectious diseases · N Engl J Med · 2026-07-29
RCTn = 607
Rockstroh et al. Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 TreatmentInfectious diseases · Lancet HIV · 2026-02-25
RCTn = 536
Rockstroh et al. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialInfectious diseases · Lancet · 2026-02-07
RCTn = 514
Colson et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialInfectious diseases · Lancet · 2026-02-07
RCTn = 553
Orkin et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial